Search results for "phosphodiester"

showing 10 items of 176 documents

Type 5 phosphodiesterase (PDE5) and the vascular tree: from embryogenesis to aging and disease

2020

Highlights • Vascular development depends on the timely differentiation of endothelial and smooth muscle cells, that mutually influence their developmental fate. • Endothelial and vascular smooth muscle cell (VSMC) compartments can mutually influence cell and tissue modifications during vascular aging and in vascular disease. • Keeping in mind that PDE5 is mainly expressed in VSMCs, we surveyed the literature on the role of PDE5 in vascular development, aging and disease. • Although most results have been obtained by PDE5 pharmacological inhibition, no data are available, to date, on vascular development, aging or disease following PDE5 genetic ablation.

0301 basic medicineCell typeAgingVascular smooth muscleMyocytes Smooth MuscleVSMCsEmbryonic DevelopmentECsContext (language use)DiseaseBiologyMuscle Smooth VascularArticle03 medical and health sciences0302 clinical medicinenitric oxidevascular smooth muscle cellsHumansBioresorbable vascular scaffoldCyclic Nucleotide Phosphodiesterases Type 5ECEmbryogenesisPhosphodiesteraseVascular agingCell biologycGMPSettore MED/23ECs; PDE5; VSMCs; cGMP; nitric oxide030104 developmental biologyVascular aging; vascular smooth muscle cells; phosphodiesterasePDE5phosphodiesterase030217 neurology & neurosurgeryFunction (biology)Developmental Biology
researchProduct

Acid sphingomyelinase – a regulator of canonical transient receptor potential channel 6 (TRPC6) activity

2019

Recent investigations propose the acid sphingomyelinase (ASM)/ceramide system as a novel target for antidepressant action. ASM catalyzes the breakdown of the abundant membrane lipid sphingomyelin to the lipid messenger ceramide. This ASM‐induced lipid modification induces a local shift in membrane properties, which influences receptor clustering and downstream signaling. Canonical transient receptor potential channels 6 (TRPC6) are non‐selective cation channels located in the cell membrane that play an important role in dendritic growth, synaptic plasticity and cognition in the brain. They can be activated by hyperforin, an ingredient of the herbal remedy St. John’s wort for treatment of de…

0301 basic medicineCeramideMedizinCeramidesPC12 CellsBiochemistryFIASMATRPC603 medical and health sciencesCellular and Molecular NeuroscienceTransient receptor potential channelchemistry.chemical_compound0302 clinical medicineddc:570medicineAnimalsInstitut für Biochemie und BiologieIon channelTRPC Cation ChannelsNeuronsRatsCell biologySphingomyelin Phosphodiesterase030104 developmental biologychemistryLipid modificationAcid sphingomyelinaseSphingomyelin030217 neurology & neurosurgerymedicine.drugJournal of Neurochemistry
researchProduct

Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences

2016

Chronic respiratory diseases affect millions of people every day. According to the World Health Organization estimates, ~235 million people suffer from asthma, ~64 million suffer from chronic obstructive pulmonary disease (COPD), and millions more suffer from allergic rhinitis around the world. In recent last years, the first phosphodiesterase 4 (PDE4) inhibitor, roflumilast, was approved as a treatment to reduce the risk of exacerbations in stable and severe COPD associated with chronic bronchitis and a history of exacerbations. PDE4 exists as four subtypes (A, B, C, and D) each with a capacity to degrade cAMP, a second messenger involved in inflammatory responses. PDE4 inhibitors inhibit …

0301 basic medicineChronic bronchitisPhosphodiesterase InhibitorsPharmacologyPulmonary Disease Chronic Obstructive03 medical and health sciencesPDE4BDrug DiscoverymedicineAnimalsHumansRespiratory systemRoflumilastAsthmaPharmacologyCOPDPhosphoric Diester Hydrolasesbusiness.industryPhosphodiesterasemedicine.diseaseIsoenzymesDiarrhea030104 developmental biologymedicine.symptombusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency

2017

Disclaimer: This diagnostic guideline is intended as an educational resource and represents the opinions of the authors, and is not representative of recommendations or policy of the American College of Medical Genetics and Genomics (ACMG). The information should be considered a consensus based on expert opinion, as more comprehensive levels of evidence were not available in the literature in all cases. Background: Acid sphingomyelinase deficiency (ASMD) is a rare, progressive, and often fatal lysosomal storage disease. The underlying metabolic defect is deficiency of the enzyme acid sphingomyelinase that results in progressive accumulation of sphingomyelin in target tissues. ASMD manifests…

0301 basic medicineGuias de prática clínica como assuntomedicine.medical_specialtyConsensusLysosomal storage disorderClinical Decision-MakingMEDLINEDiseaseDiagnosis Differential03 medical and health sciencesSpecial Article0302 clinical medicineInternal medicinemedicineHumansacid sphingomyelin deficiencyGenetic TestingDisease management (health)Intensive care medicineDoenças de Niemann-PickGenetics (clinical)PulmonologistsGenetic testingmedicine.diagnostic_testbusiness.industryNiemann-Pick disease types A and BEvidence-based medicineGuidelineNiemann-Pick Disease Type BNiemann-Pick Disease Type A030104 developmental biologyEndocrinologyPhenotypeSphingomyelin PhosphodiesteraseMutationPractice Guidelines as TopicMedical geneticslysosomal storage disorderbusiness030217 neurology & neurosurgeryAlgorithmsBiomarkersAcid sphingomyelin deficiency
researchProduct

Molecular Mechanism of the site-specific self-cleavage of the RNA phosphodiester backbone by a Twister Ribozyme

2017

Published as part of the special collection of articles derived from the 10th Congress on Electronic Structure: Principles and Applications (ESPA-2016). The catalytic activity of some classes of natural RNA, named as ribozymes, has been discovered just in the past decades. In this paper, the cleavage of the RNA phosphodiester backbone has been studied in aqueous solution and in a twister ribozyme from Oryza sativa. The free energy profiles associated with a baseline substrate-assisted mechanism for the reaction in the enzyme and in solution were computed by means of free energy perturbation methods within hybrid QM/MM potentials, describing the chemical system by the M06-2× functional and t…

0301 basic medicineKIEsReaction mechanismbiologyChemistryRibozymeNanotechnology010402 general chemistryfree energy profiles01 natural sciencesQM/MM0104 chemical sciencesFree energy perturbationQM/MM03 medical and health sciencestwister ribozyme030104 developmental biologyComputational chemistryKinetic isotope effectPhosphodiester bondbiology.proteinreaction mechanismPhysical and Theoretical ChemistryHairpin ribozymeBond cleavage
researchProduct

Regulation of PDE5 expression in human aorta and thoracic aortic aneurysms

2019

AbstractAneurysms and dissections affecting thoracic aorta are associated with smooth muscle cell (SMC) dysfunction. NO/cGMP signaling pathway in smooth muscle cells has been shown to be affected in sporadic thoracic aortic aneurysms. We analyzed the mRNA levels of PDE5, a cGMP-hydrolyzing enzyme highly expressed in aortic SMCs, that regulates arterious vascular tone by lowering cGMP levels. We found that aortic tissue obtained from Marfan, tricuspid and bicuspid thoracic aneurysms expressed lower levels of PDE5 mRNA compared to control aortas. In particular, we found that affected aortas showed lower levels of all the PDE5A isoforms, compared to control aortas. Transfection of vascular SMC…

0301 basic medicineMaleCelllcsh:MedicineStimulationMuscle Smooth VascularAortic aneurysmchemistry.chemical_compound0302 clinical medicinePDE5 expression human aorta and thoracic aortic aneurysmsMyocyteThoracic aortalcsh:ScienceSettore BIO/16MultidisciplinaryTransfectionMiddle AgedIsoenzymesmedicine.anatomical_structurecardiovascular systemFemaleGene isoformAdultmedicine.medical_specialtyMyocytes Smooth MuscleArticleGene Expression Regulation EnzymologicNitric oxide03 medical and health sciencesmedicine.arteryInternal medicinemedicineHumansSettore MED/05 - Patologia ClinicaAgedCyclic Nucleotide Phosphodiesterases Type 5Aortic Aneurysm Thoracicbusiness.industrylcsh:Rmedicine.disease030104 developmental biologyEndocrinologychemistryRisk factorsthoracic aortic aneurysmslcsh:QAngiogenesisPDE5business030217 neurology & neurosurgery
researchProduct

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

2017

Background and Purpose Mirabegron has been classified as a β3-adrenoceptor agonist approved for overactive bladder syndrome. We investigated possible cardiac effects of mirabegron in the absence or presence of β-adrenoceptor subtype antagonists. In view of its phenylethanolamine structure, we investigated whether mirabegron has indirect sympathomimetic activity by using neuronal uptake blockers. Experimental Approach Right atrial trabeculae, from non-failing hearts, were paced and contractile force measured at 37°C. Single concentrations of mirabegron were added in the absence or presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), β3 (L-748,337), β1 (CGP 20712A),…

0301 basic medicinePharmacologyAgonistmedicine.medical_specialtyIBMXContraction (grammar)PhenoxybenzamineChemistrymedicine.drug_classAdrenergicPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biologyEndocrinologyInternal medicineDesipraminemedicinePhosphodiesterase inhibitorMirabegronmedicine.drugBritish Journal of Pharmacology
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia

2018

javax.xml.bind.JAXBElement@6f8948ff Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe pulmonary complications as pulmonary hypertension. Because nitric oxide (NO) is a critical mediator in the development of pulmonary hypertension, the modulators of its downstream function may become target of pharmacological interventions aimed at alleviating the impact of this condition. Here, we investigate the effects of an early administration of phosphodiesterase-5 inhibitor in rats where pulmonary artery hypertension was induced by chronic exposure to hypoxia. javax.xml.bind.JAXBElement@162dc677 Rats were divided into three groups: normoxic control, hypoxic with …

0301 basic medicinemedicine.medical_specialtynitrites and nitratesPhysiologySildenafilsildenafil030204 cardiovascular system & hematologyphosphodiesterase 5lcsh:PhysiologyNitric oxideendothelial NO synthase; nitric oxide; nitrites and nitrates; phosphodiesterase 5; pulmonary hypertension; pulmonary vascular remodeling; right heart failure; sildenafil03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidePhysiology (medical)medicine.arteryInternal medicinepulmonary hypertensionmedicineendothelial NO synthaseOriginal ResearchCardiopulmonary diseaseLunglcsh:QP1-981business.industryright heart failureHypoxia (medical)medicine.diseasePulmonary hypertension030104 developmental biologymedicine.anatomical_structurechemistryVentriclePulmonary arteryCardiologymedicine.symptombusinesspulmonary vascular remodelingFrontiers in Physiology
researchProduct

β-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E 2 -inhibitory effects in human neutrophils

2000

Human neutrophils were treated for 4 h with a combination of salbutamol (1 µM), a β2-adrenoceptor agonist, and rolipram (30 µM), a selective phosphodiesterase 4 inhibitor, to investigate whether this treatment produces up-regulation of phosphodiesterase activity with functional consequences. Anion-exchange chromatography coupled with the use of selective activators and inhibitors demonstrated that a phosphodiesterase activity with characteristics of the isoenzyme type 4 was increased in drug-treated cells. Kinetic analysis showed a ~1.5-fold increase in V max without alteration of K m values. The augmented phosphodiesterase activity in drug-treated cells was abolished by actinomycin D. Cycl…

AdultAgonistmedicine.medical_specialtyNeutrophilsmedicine.drug_classStimulationIn Vitro TechniquesBiologyDinoprostoneNeutrophil Activationchemistry.chemical_compoundPDE4BDownregulation and upregulationSuperoxidesInternal medicineCyclic AMPmedicineHumansAlbuterolRNA MessengerEnzyme InhibitorsProstaglandin E2RolipramPharmacologyReverse Transcriptase Polymerase Chain ReactionSuperoxideZymosanZymosanGeneral MedicineAdrenergic AgonistsCyclic Nucleotide Phosphodiesterases Type 4Up-RegulationEndocrinologychemistry3'5'-Cyclic-AMP PhosphodiesterasesReceptors Adrenergic beta-2Roliprammedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct